Economic Manufacture of Mesenchymal Stem Cells on a Commercial Scale is Limiting Factor to Therapeutic Use
Cynata Therapeutics Limited is a regenerative medicine company, listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).
UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of hESC derivation. [Read more…]